Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction

Cardiovascular Therapeutics

Volumn 34, Issue 4, 2016, Pages 191-198

  Kobalava, Zhanna ^a   Kotovskaya, Yulia ^a   Averkov, Oleg ^a   Pavlikova, Elena ^a   Moiseev, Valentine ^a   Albrecht, Diego ^b   Chandra, Priya ^c,e   Ayalasomayajula, Surya ^c   Prescott, Margaret F ^b   Pal, Parasar ^d   Langenickel, Thomas H ^b   Jordaan, Pierre ^b   Rajman, Iris ^b  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d Novartis Healthcare Private Limited   (India)

^e GENENTECH INC   (United States)

Author keywords

Heart failure; LCZ696; Pharmacodynamics; Pharmacokinetics; Sacubitril valsartan

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; ACETYLSALICYLIC ACID; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; CYCLIC GMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; MEMBRANE METALLOENDOPEPTIDASE; NIFEDIPINE; NITRIC ACID DERIVATIVE; RENIN; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; VALSARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERKALEMIA; HYPOTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; NEW YORK HEART ASSOCIATION CLASS; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PR PROLONGATION; PRIORITY JOURNAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84978986133     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12183     Document Type: Article

References (22)

1. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010;50:401–414.
2. Wang BH, Von Lueder TG, Kompa AR, et al. Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. Int J Cardiol 2015;186:104–105.
3. von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015;8:71–78.
4. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics. Eur Heart J 2013;34:886–893c.
5. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47–72.
6. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82–C97.
7. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255–1266.
8. McMurray JJ, Packer M, Desai AS, et al. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
9. Entresto Prescribing Information. US Food and Drug Administration Web Site [Internet]. 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf.
10. Entresto Summary of Product Characteristics. EMA Web Site [Internet]. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf.
11. Liao WC, Vesterqvist O, Delaney C, et al. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. Br J Clin Pharmacol 2003;56:395–406.
12. Azizi M, Menard J, Bissery A, Guyene TT, Bura-Riviere A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007;2:947–955.
13. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291(Pt 1):83–88.
14. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol 2008;101:3–8.
15. Cioffi G, Tarantini L, Stefenelli C, et al. Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. J Card Fail 2006;12:608–615.
16. Abassi Z, Golomb E, Keiser HR. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabolism 1992;41:683–685.
17. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145–151.
18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717.
19. Miura S, Suematsu Y, Matsuo Y, et al. Angiotensin II Receptor-Neprilysin Inhibitor, LCZ696 Blocked Aldosterone Synthesis in Human Adrenocortical Cell Line. Eur Heart J 2015;36(Suppl 1):662.
20. Ayalasomayajula S, Jordaan P, Pal P, et al. Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfarin. Clin Pharmacol Biopharm 2015;4:147. doi:10.4172/2167-065X.1000147.
21. Prasad PP, Yeh CM, Gurrieri P, Glazer R, McLeod J. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 2002;40:801–807.
22. Bodey F, Hopper I, Krum H. Neprilysin inhibitors preserve renal function in heart failure. Int J Cardiol 2015;179:329–330.